Drug
ASM8
ASM8 is a pharmaceutical drug with 3 clinical trials. Historical success rate of 50.0%.
Total Trials
3
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
50.0%
Based on 1 completed trials
Completion Rate
50%(1/2)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Terminated
1(33%)
Phase Distribution
Ph phase_2
2
67%
Ph phase_1
1
33%
Phase Distribution
1
Early Stage
2
Mid Stage
0
Late Stage
Phase Distribution3 total trials
Phase 1Safety & dosage
1(33.3%)
Phase 2Efficacy & side effects
2(66.7%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
33.3%
1 of 3 finished
Non-Completion Rate
66.7%
2 ended early
Currently Active
0
trials recruiting
Total Trials
3
all time
Status Distribution
Completed(1)
Terminated(2)
Detailed Status
Withdrawn1
Completed1
Terminated1
Development Timeline
Analytics
Development Status
Total Trials
3
Active
0
Success Rate
50.0%
Most Advanced
Phase 2
Trials by Phase
Phase 11 (33.3%)
Phase 22 (66.7%)
Trials by Status
withdrawn133%
completed133%
terminated133%
Recent Activity
0 active trials
Showing 3 of 3
completedphase_1
Multiple Dose ASM8 in Mild Asthmatics
NCT00264966
terminatedphase_2
Safety and Efficacy of Two Dosages of Inhaled TPI ASM8 Compared to Placebo in Mild to Moderate Asthmatic Patients
NCT00402948
withdrawnphase_2
A Single Blind Study to Evaluate the Safety, Tolerability and Explore the Efficacy of 8.0 mg ASM8 Inhaled Daily for 14 Days in Severe Asthma
NCT01380236
Clinical Trials (3)
Showing 3 of 3 trials
NCT00264966Phase 1
Multiple Dose ASM8 in Mild Asthmatics
NCT00402948Phase 2
Safety and Efficacy of Two Dosages of Inhaled TPI ASM8 Compared to Placebo in Mild to Moderate Asthmatic Patients
NCT01380236Phase 2
A Single Blind Study to Evaluate the Safety, Tolerability and Explore the Efficacy of 8.0 mg ASM8 Inhaled Daily for 14 Days in Severe Asthma
All 3 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 3